LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 269 filers reported holding LIGAND PHARMACEUTICALS INC in Q4 2019. The put-call ratio across all filers is 1.95 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $650,590 | -25.3% | 8,900 | -27.0% | 0.00% | 0.0% |
Q4 2023 | $871,324 | +2.2% | 12,200 | -14.3% | 0.00% | 0.0% |
Q3 2023 | $852,781 | +37.5% | 14,232 | +158.2% | 0.00% | 0.0% |
Q1 2022 | $620,000 | -67.1% | 5,512 | -54.8% | 0.00% | -66.7% |
Q4 2021 | $1,884,000 | +193.9% | 12,200 | +165.2% | 0.01% | +100.0% |
Q3 2021 | $641,000 | -35.3% | 4,600 | -29.2% | 0.00% | -25.0% |
Q1 2021 | $990,000 | +145.7% | 6,500 | +80.6% | 0.00% | +100.0% |
Q2 2020 | $403,000 | -77.3% | 3,600 | -78.8% | 0.00% | -84.6% |
Q4 2019 | $1,772,000 | +78.1% | 17,000 | +70.0% | 0.01% | +62.5% |
Q3 2019 | $995,000 | -65.4% | 10,000 | -60.3% | 0.01% | -68.0% |
Q2 2019 | $2,877,000 | +1244.4% | 25,200 | +1382.4% | 0.02% | +1150.0% |
Q1 2019 | $214,000 | -14.4% | 1,700 | -7.8% | 0.00% | +100.0% |
Q4 2018 | $250,000 | -92.6% | 1,844 | -85.0% | 0.00% | -94.4% |
Q3 2018 | $3,376,000 | +41.7% | 12,300 | +7.0% | 0.02% | +38.5% |
Q2 2018 | $2,383,000 | +11815.0% | 11,500 | +5650.0% | 0.01% | – |
Q2 2015 | $20,000 | – | 200 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
KNOTT DAVID M | 353,041 | $25,673,000 | 16.20% |
Stonepine Capital Management, LLC | 160,919 | $11,702,000 | 12.38% |
VILLERE ST DENIS J & CO LLC | 635,758 | $46,232,000 | 3.94% |
CARDINAL CAPITAL MANAGEMENT LLC /CT | 982,049 | $71,415,000 | 3.51% |
Elk Creek Partners, LLC | 246,251 | $17,907,000 | 3.08% |
Tygh Capital Management, Inc. | 151,792 | $11,038,000 | 2.47% |
Roubaix Capital, LLC | 20,034 | $1,457,000 | 2.21% |
Conestoga Capital Advisors, LLC | 648,603 | $47,166,000 | 1.38% |
RICE HALL JAMES & ASSOCIATES, LLC | 338,376 | $24,607,000 | 1.38% |
Ikarian Capital, LLC | 200,000 | $14,544,000 | 1.09% |